Silexion Therapeutics’ SIL204 emerges as a potential game-changer in KRAS-driven cancer treatment
Silexion Therapeutics (NASDAQ: SLXN) has taken a major step forward in oncology research, unveiling new preclinical data on its experimental therapy, SIL204. The clinical-stage biotechnology ... Read More
Tempus AI and Stemline Therapeutics partner to advance AI-driven ESR1 mutation testing in metastatic breast cancer
Tempus AI, Inc. (NASDAQ: TEM) and Stemline Therapeutics, Inc., a wholly owned subsidiary of the Menarini Group, have announced a collaboration to integrate Tempus Next, ... Read More
Kinnate Biopharma agrees to merger with XOMA, boosting shareholder value and advancing cancer research
Kinnate Biopharma Inc. (Nasdaq: KNTE), a leading clinical-stage precision oncology company, has announced a definitive merger agreement with XOMA Corporation, setting the stage for a ... Read More